The Role of Neoadjuvant and Adjuvant Chemotherapy in Pancreatic Cancer

Pancreatic cancer is an aggressive malignancy. Recurrences are very high despite high-quality surgery necessitating adjuvant therapy. The evolution of adjuvant therapy took several decades and gradually evolved from single-agent chemotherapy to multi-agent chemotherapy. The two important agents that...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of surgical oncology 2024-05, Vol.15 (Suppl 2), p.315-321
Main Authors: K, Govind Babu, Koyyala, Venkata Pradeep Babu
Format: Article
Language:English
Subjects:
Medicine
Medicine & Public Health
Oncology
Review Article
Surgery
Surgical Oncology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic cancer is an aggressive malignancy. Recurrences are very high despite high-quality surgery necessitating adjuvant therapy. The evolution of adjuvant therapy took several decades and gradually evolved from single-agent chemotherapy to multi-agent chemotherapy. The two important agents that are active in pancreatic cancer are 5-fluorouracil and gemcitabine, and with several combinations showing better results in the subsequent trials, the most recent trial PRODIGE 24 shows a median survival of 54.4 months. The role of neoadjuvant therapy is still evolving in resectable cancers. The role of adjuvant radiotherapy is not well defined due to controversial results from historical trials.
ISSN:0975-7651
0976-6952
DOI:10.1007/s13193-024-01938-6